State of art and recent developments of anti-cancer strategies based on TRAIL. Recent Pat Anticancer Drug Discov 2012;7(2):207-17.
. TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) 2012;123(9):547-55.
. TRAIL, a new weapon against neointimal hyperplasia. Cardiology 2012;123(2):94-6.
. TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide. Cytokine 2012;60(1):43-6.
. TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases. Curr Drug Targets 2012;13(9):1215-21.
. TRAIL shows potential cardioprotective activity. Invest New Drugs 2012;30(3):1257-60.
. Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 2011;215(2):452-8.
. Circulating TRAIL shows a significant post-partum decline associated to stressful conditions. PLoS One 2011;6(12):e27011.
. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 2011;17(4):762-70.
. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011;17(9):2712-24.
. Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opin Ther Targets 2011;15(8):931-42.
. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol 2011;331(1):136-42.
.